Report cover image

Global Hormone Sensitive Prostate Cancer Drugs Market Growth (Status and Outlook) 2026-2032

Publisher LP Information, Inc.
Published Mar 06, 2026
Length 110 Pages
SKU # LPI20939746

Description

The global Hormone Sensitive Prostate Cancer Drugs market size is predicted to grow from US$ 168 million in 2025 to US$ 343 million in 2032; it is expected to grow at a CAGR of 10.9% from 2026 to 2032.

Hormone-sensitive prostate cancer (HSPC) drugs are a class of medications used to treat prostate cancer that is dependent on androgens, or male hormones, to grow and spread. These drugs work by reducing or blocking the production of androgens in the body, mainly testosterone, or by inhibiting androgen receptors on cancer cells. This hormonal therapy aims to slow down or stop the progression of cancer by depriving cancer cells of the hormones they need to grow. Common drugs in this category include androgen deprivation therapies (ADTs) like LHRH agonists, LHRH antagonists, and anti-androgens.

United States market for Hormone Sensitive Prostate Cancer Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Hormone Sensitive Prostate Cancer Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Hormone Sensitive Prostate Cancer Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Hormone Sensitive Prostate Cancer Drugs players cover Novartis, Merc & Co., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LPI (LP Information)' newest research report, the “Hormone Sensitive Prostate Cancer Drugs Industry Forecast” looks at past sales and reviews total world Hormone Sensitive Prostate Cancer Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Hormone Sensitive Prostate Cancer Drugs sales for 2026 through 2032. With Hormone Sensitive Prostate Cancer Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hormone Sensitive Prostate Cancer Drugs industry.

This Insight Report provides a comprehensive analysis of the global Hormone Sensitive Prostate Cancer Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Hormone Sensitive Prostate Cancer Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hormone Sensitive Prostate Cancer Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hormone Sensitive Prostate Cancer Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hormone Sensitive Prostate Cancer Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Hormone Sensitive Prostate Cancer Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Androgen Ablation Therapy
Anti-androgens
Chemotherapy
Targeted Therapy

Segmentation by Application:
Hospitals
Clinics
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Merc & Co.
Bristol-Myers
Dendreon Corporation
GlaxoSmithKline
Ferring
Roche
Celgen
Amgen
Teva
Bayer
Pfizer

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

110 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Hormone Sensitive Prostate Cancer Drugs Market Size by Player
4 Hormone Sensitive Prostate Cancer Drugs by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Hormone Sensitive Prostate Cancer Drugs Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us